Biotechnology Cancer Cures Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Biotechnology Cancer Cures

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Jim Oravetz who wrote (161)	6/27/2000 7:51:00 AM
From: Jim Oravetz	Read Replies (1) of 226

TWO-DRUG COMBINATION THERAPY SHOWS PROMISE AGAINST MELANOMA Melanoma researchers at University of California, San Diego (UCSD) have developed a new drug-combination therapy that has proven in Phase II clinical trials to be significantly better at extending patients? lives than any other drug therapy. The two drugs, tamoxifen and cisplatin, are commonly used chemotherapeutic agents. Interestingly, neither drug, when used alone, has proven effective against melanoma. ?For reasons that aren?t yet clear, this combination creates a synergism that is highly toxic to melanoma cells,? said Edward F. McClay, M.D., principal investigator of the study and director of the Melanoma Care Unit at UCSD Cancer Center. Results of the clinical trial are being published in the July 2000 issue of the British Journal of Cancer. The clinical trial was based upon earlier laboratory work in which McClay and colleagues first identified this synergistic interaction. snip.... health.ucsd.edu Jim

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next